IS4282A - Leysnistýrð skammtaform af Azithromycín - Google Patents

Leysnistýrð skammtaform af Azithromycín

Info

Publication number
IS4282A
IS4282A IS4282A IS4282A IS4282A IS 4282 A IS4282 A IS 4282A IS 4282 A IS4282 A IS 4282A IS 4282 A IS4282 A IS 4282A IS 4282 A IS4282 A IS 4282A
Authority
IS
Iceland
Prior art keywords
azithromycin
solvent
dosage form
controlled dosage
controlled
Prior art date
Application number
IS4282A
Other languages
English (en)
Inventor
J. Curatolo William
L. Friedman Hylar
W. Korsmeyer Richard
R. Le Mott Steven
Original Assignee
Pfizer, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22900590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS4282(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer, Inc. filed Critical Pfizer, Inc.
Publication of IS4282A publication Critical patent/IS4282A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Detergent Compositions (AREA)
IS4282A 1994-05-06 1995-05-02 Leysnistýrð skammtaform af Azithromycín IS4282A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23909494A 1994-05-06 1994-05-06

Publications (1)

Publication Number Publication Date
IS4282A true IS4282A (is) 1995-11-07

Family

ID=22900590

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4282A IS4282A (is) 1994-05-06 1995-05-02 Leysnistýrð skammtaform af Azithromycín

Country Status (42)

Country Link
US (2) US6068859A (is)
EP (1) EP0758244B2 (is)
JP (1) JP2977907B2 (is)
KR (1) KR100232297B1 (is)
CN (1) CN1096862C (is)
AP (1) AP548A (is)
AT (1) ATE209497T1 (is)
AU (1) AU680356B2 (is)
BG (1) BG63152B1 (is)
BR (1) BR9501929A (is)
CA (1) CA2189658C (is)
CO (1) CO4290346A1 (is)
CZ (1) CZ292360B6 (is)
DE (1) DE69524214T3 (is)
DK (1) DK0758244T4 (is)
DZ (1) DZ1880A1 (is)
ES (1) ES2163504T5 (is)
FI (1) FI964452A7 (is)
HR (1) HRP950277B1 (is)
HU (1) HUT77530A (is)
IL (3) IL131308A (is)
IS (1) IS4282A (is)
LV (1) LV11729B (is)
MA (1) MA23537A1 (is)
MX (1) MX9605419A (is)
MY (1) MY113059A (is)
NO (1) NO315453B1 (is)
NZ (1) NZ283160A (is)
OA (1) OA10320A (is)
PE (1) PE4796A1 (is)
PL (1) PL179910B1 (is)
PT (1) PT758244E (is)
RO (1) RO114740B1 (is)
RU (1) RU2130311C1 (is)
SI (1) SI9520049A (is)
SK (1) SK282854B6 (is)
TN (1) TNSN95051A1 (is)
TW (1) TW420616B (is)
UA (1) UA41995C2 (is)
UY (1) UY23958A1 (is)
WO (1) WO1995030422A1 (is)
ZA (1) ZA953627B (is)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
SK282854B6 (sk) * 1994-05-06 2002-12-03 Pfizer Inc. Dávkovacia forma s riadeným uvoľňovaním obsahujúca azitromycín
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
WO1998022096A1 (en) * 1996-11-15 1998-05-28 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6551616B1 (en) 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20040028735A1 (en) * 1997-11-14 2004-02-12 Unchalee Kositprapa Pharmaceutical formulation
US6306642B1 (en) * 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
TW570814B (en) * 1998-03-26 2004-01-11 Fujisawa Pharmaceutical Co Sustained-release pharmaceutical composition
CN1209098C (zh) * 1998-06-03 2005-07-06 阿尔扎有限公司 提供药物长效治疗的方法和装置
DE19850445A1 (de) * 1998-11-02 2000-05-04 Falk Pharma Gmbh Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
JP2002528486A (ja) * 1998-11-02 2002-09-03 アルザ・コーポレーション 有効物質の送達制御
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE60039802D1 (de) * 1999-02-10 2008-09-25 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
US6878386B1 (en) * 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
EP1207852A4 (en) * 1999-09-02 2009-11-11 Nostrum Pharmaceuticals Inc ORAL PHARMACEUTICALS WITH TAXED RELEASE FOR ORAL ADMINISTRATION
JP4040878B2 (ja) * 1999-12-09 2008-01-30 レキット ベンキーザー ヘルスケア (ユーケイ) リミテッド 治療薬
JP4100910B2 (ja) * 1999-12-23 2008-06-11 ファイザー・プロダクツ・インク ヒドロゲル駆動の薬物剤形
AU1724301A (en) 1999-12-23 2001-07-09 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US20050175959A1 (en) * 2000-03-14 2005-08-11 Coll Partners Ltd. System for the controlled delivery of an active material to a dental site
IL135061A0 (en) * 2000-03-14 2001-05-20 Ahron Jodaikin Strategic targeted fluoridation and chemical treatment of teeth
US6569152B2 (en) 2000-03-21 2003-05-27 Farrington Pharmaceuticals, Llc Sustained release delivery systems for solutes
FR2811571B1 (fr) * 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
FR2821745B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
NZ528957A (en) * 2001-04-18 2005-05-27 Nostrum Pharmaceuticals Inc A novel coating for a sustained release pharmaceutical composition
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1671978A1 (en) 2001-05-22 2006-06-21 Pfizer Products Inc. New Cristal Form of Azithromycin
US20080305173A1 (en) * 2001-07-31 2008-12-11 Beuford Arlie Bogue Amorphous drug beads
YU8804A (sh) * 2001-08-21 2006-08-17 Pfizer Products Inc. Jedno-dozni azitromicin
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
WO2003053428A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Controlled release dosage form having improved drug release properties
AU2002348884A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Directly compressible formulations of azithromycin
CA2470055A1 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Methods for wet granulating azithromycin
RU2212242C1 (ru) * 2001-12-24 2003-09-20 Закрытое акционерное общество "Брынцалов-А" Антибиотик сумазид
CN1309370C (zh) 2002-02-01 2007-04-11 辉瑞产品公司 使用改进的喷雾干燥设备制备均匀喷雾干燥的固体非晶形药物分散体的方法
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
MXPA04007427A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Formulaciones de azitromicina granuladas por via seca.
KR100758045B1 (ko) * 2002-02-01 2007-09-11 화이자 프로덕츠 인크. 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
ATE407674T1 (de) * 2002-04-09 2008-09-15 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
RU2283116C2 (ru) * 2002-05-27 2006-09-10 Курский государственный медицинский университет Способ увеличения выживаемости изолированного кожного лоскута "на ножке" у животных с пониженным антиоксидантным фоном
AU2003245504A1 (en) * 2002-06-14 2003-12-31 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
GB0214013D0 (en) * 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
WO2004041244A2 (en) * 2002-10-30 2004-05-21 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
US7351430B2 (en) * 2002-11-06 2008-04-01 Uluru Inc. Shape-retentive hydrogel particle aggregates and their uses
US7811605B2 (en) * 2002-11-06 2010-10-12 Uluru Inc. Method of formation of shape-retentive aggregates of gel particles and their uses
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
MEP10808A (en) 2002-12-16 2010-06-10 Kissei Pharmaceutical Solid drug for oral use
EP1589951B1 (en) 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
FR2850577B1 (fr) * 2003-02-03 2005-04-15 Ethypharm Sa Particules enrobees a gout masque, leur procede de preparation et comprimes orodispersibles contenant lesdites particules
RU2241985C1 (ru) * 2003-03-27 2004-12-10 Томский политехнический университет Способ количественного определения азитромицина дигидрата методом инверсионной вольтамперометрии
BRPI0410098A (pt) * 2003-05-06 2006-05-16 Nirmal Mulye formulação de liberação controlada de derivados de eritromicina
US7063862B2 (en) 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
CA2673334C (en) * 2003-06-16 2013-11-12 Andrx Pharmaceuticals, Llc Oral extended-release composition
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
WO2005009365A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8425936B2 (en) 2003-07-21 2013-04-23 Shionogi Inc. Antibiotic product, use and formulation thereof
EP1648407A4 (en) 2003-07-21 2011-08-31 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, CORRESPONDING USE AND FORMULATION
JP2005041838A (ja) * 2003-07-24 2005-02-17 Matsumoto Shika Univ バイオフィルム除去剤
US20050025829A1 (en) * 2003-07-29 2005-02-03 Kim Cherng-Ju Controlled drug release tablets
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) * 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
AU2004273830B2 (en) 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
CN1889932A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 制备药用多颗粒的方法
CA2547239A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
ES2600577T3 (es) * 2003-12-04 2017-02-09 Bend Research, Inc. Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
BRPI0416535A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
JP2007513139A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053654A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release dosage forms of azithromycin
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8697031B2 (en) * 2004-06-04 2014-04-15 Case Western Reserve University Dual function polymer micelles
CA2569961A1 (en) * 2004-06-10 2005-12-29 Glatt Air Techniques, Inc Controlled release pharmaceutical formulation
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
AU2005269981A1 (en) 2004-07-02 2006-02-09 Bonck, John A Tablet for pulsed delivery
PL2801355T3 (pl) 2004-10-08 2015-10-30 Fwp Ip Aps Kompozycje farmaceutycznie o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
JP2008524317A (ja) * 2004-12-21 2008-07-10 ファイザー・プロダクツ・インク 腸溶コーティングされたアジスロマイシン多粒子
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1912629A4 (en) * 2005-07-08 2012-09-12 Univ Arkansas ASYMMETRIC COATING COMPRESSOR
US8858993B2 (en) * 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
EP1749519A1 (de) * 2005-08-05 2007-02-07 Schering Aktiengesellschaft Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
WO2007073596A1 (en) * 2005-12-27 2007-07-05 Labopharm Inc. Degradable polymeric microsphere composition
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US20070243248A1 (en) * 2006-04-14 2007-10-18 Cherukuri S Rao Rapidly disintegrating solid oral dosage form of liquid dispersions
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US20070281894A1 (en) * 2006-06-05 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
US7713549B2 (en) * 2006-06-30 2010-05-11 Board Of Trustees Of The University Of Arkansas Extended release perforated tablet
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US7910135B2 (en) * 2006-10-13 2011-03-22 Uluru Inc. Hydrogel wound dressing and biomaterials formed in situ and their uses
US20110052688A1 (en) * 2006-11-21 2011-03-03 San-Laung Chow Solid dispersion composition
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
WO2008065504A1 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
CN100441196C (zh) * 2006-12-15 2008-12-10 北京化工大学 一种制备微粉化阿奇霉素的方法
US8895061B2 (en) * 2007-03-02 2014-11-25 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
US20080228268A1 (en) * 2007-03-15 2008-09-18 Uluru, Inc. Method of Formation of Viscous, Shape Conforming Gels and Their Uses as Medical Prosthesis
BRPI0700969A (pt) * 2007-03-22 2008-11-04 Ouro Fino Participacoes E Empr composição para o tratamento de afecções bacterianas e inflamatórias em animais de companhia
US7850453B2 (en) * 2007-08-08 2010-12-14 Coll Partners Ltd. Reshapable device for fixation at a dental site
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
WO2009033766A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009033748A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of osteostatin, alone or in combination with thymopentin, as a therapeutic agent
WO2009040020A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Amylin as a therapeutic agent
JP2010539065A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのペプチドの使用
AU2008297931A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of RGDSPASSKP and optionally angiotensin II as therapeutic agents in the treatment of Eg S. pneumoniae infections
AU2008297542A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100197600A1 (en) 2007-09-11 2010-08-05 Dorian Bevec Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent
AU2008303957A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Big gastrin I as a therapeutic agent
WO2009043440A2 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
LT2273983T (lt) 2008-05-09 2016-10-25 Grünenthal GmbH Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2198859A1 (en) * 2008-12-17 2010-06-23 Losan Pharma GmbH Melt-coated pharmaceutical composition with fast release
PE20121067A1 (es) 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
PE20120631A1 (es) 2009-07-22 2012-06-06 Gruenenthal Chemie Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion
NZ599524A (en) 2009-11-09 2014-04-30 Spotlight Technology Partners Llc Polysaccharide based hydrogels
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
WO2011113507A2 (en) 2010-03-15 2011-09-22 Ulrich Dietz Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns
WO2011125075A2 (en) 2010-04-08 2011-10-13 Fdc Limited A novel gastroretentive delivery of macrolide
CN103269688A (zh) 2010-09-02 2013-08-28 格吕伦塔尔有限公司 包含无机盐的抗破碎剂型
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2823628A1 (en) 2011-01-05 2012-07-12 Hospira, Inc. Spray drying vancomycin
AU2012292418B2 (en) 2011-07-29 2017-02-16 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
DK2741766T3 (en) * 2011-08-08 2016-01-11 Aptalis Pharma Ltd Process for dissolving solid compositions containing digestive enzymes
WO2013035081A2 (de) * 2011-09-07 2013-03-14 JÄNISCH, Melisa Optimale formulierung zur freisetzung eines wirkstoffes im dickdarm
US10653631B2 (en) 2011-09-07 2020-05-19 Roland SAUR-BROSCH Optimal colon targeting technology
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
WO2013103801A1 (en) * 2012-01-04 2013-07-11 Hospira, Inc. Pharmaceutical spray drying
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
AR090695A1 (es) 2012-04-18 2014-12-03 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
US20150202161A1 (en) * 2012-08-20 2015-07-23 O-Ray Pharma, Inc. Process for manufacturing drug delivery formulations
CN103860515A (zh) * 2012-12-10 2014-06-18 中国科学院上海药物研究所 阿奇霉素渗透泵控释片及其制备方法
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
CN105431144A (zh) 2013-06-05 2016-03-23 思康脑侒股份有限公司 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
US9668844B2 (en) 2013-11-06 2017-06-06 Colldent Y.A Ltd Device for fixation at a dental site
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
AU2016274949B2 (en) * 2015-06-10 2021-07-15 Dechra Veterinary Products, Llc Injectable antibiotic formulations and use thereof
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
WO2018190621A1 (ko) * 2017-04-10 2018-10-18 성균관대학교 산학협력단 다공성 위체류층을 포함하는 서방성 제제 및 이의 제조방법
GB201904757D0 (en) * 2019-04-04 2019-05-22 Biorelevant Com Ltd Biorelevant composition
WO2021070121A1 (en) 2019-10-11 2021-04-15 Anatara Lifesciences Limited Gastrointestinal health composition
CN112326838A (zh) * 2020-11-10 2021-02-05 湖北省宏源药业科技股份有限公司 一种改善阿奇霉素胶囊溶出曲线的测定方法
CN113116859B (zh) * 2021-04-12 2022-08-30 海南普利制药股份有限公司 阿奇霉素丸芯包衣制剂
CN113985783B (zh) * 2021-10-29 2022-09-02 中山东菱威力电器有限公司 一种冰激淋料浆有无检测电路
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
PH19293A (en) * 1982-11-15 1986-03-04 Pfizer Epimeric azahomoerythromycin,pharmaceutical composition containing the same and method of use thereof
US4851231A (en) * 1982-12-13 1989-07-25 Alza Corporation System for delivering drug in selected environment of use
US4496322A (en) 1983-05-11 1985-01-29 University Of Toronto Innovations Foundation Benzoin antimicrobial dental varnishes
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
EP0243302B1 (en) 1986-04-17 1992-01-22 Eltech Systems Corporation An electrode with a platinum metal catalyst in surface film and its use
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
IT1222309B (it) 1987-07-08 1990-09-05 Menarini Sas Utilizzazione di forme farmaceutiche per uso topico contenenti miocamicina per la terapia delle infezione da germi sensibili alla miocamicina stessa
MX12213A (es) * 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US4925674A (en) * 1988-08-25 1990-05-15 Himedics, Inc. Amoxicillin microencapsulated granules
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
AU629915B2 (en) * 1989-02-16 1992-10-15 British Technology Group Limited Dispensing device
PT94712A (pt) * 1989-07-18 1992-03-31 Alza Corp Um doseador para distribuir um ionoforo benefico
US5084267A (en) 1989-11-17 1992-01-28 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5198220A (en) 1989-11-17 1993-03-30 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5173299A (en) 1989-11-17 1992-12-22 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5230895A (en) 1990-05-01 1993-07-27 Copley Pharmaceutical Inc. Sustained released delivery system for use in the periodontal pocket
EP0528971B1 (en) * 1990-05-14 1999-09-01 JERNBERG, Gary R. Surgical implant and method incorporating chemotherapeutic agents
US5114718A (en) 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
SE9201930D0 (sv) 1992-06-24 1992-06-24 Astra Ab Gastric antibacterial treatment
TW271400B (is) * 1992-07-30 1996-03-01 Pfizer
JP2847326B2 (ja) 1992-11-30 1999-01-20 ファイザー・インク. 支持された液体膜送達デバイス
CA2173109A1 (en) * 1993-10-01 1995-04-13 Kenneth Shyer Kornman Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
SK282854B6 (sk) * 1994-05-06 2002-12-03 Pfizer Inc. Dávkovacia forma s riadeným uvoľňovaním obsahujúca azitromycín
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects

Also Published As

Publication number Publication date
WO1995030422A1 (en) 1995-11-16
US6068859A (en) 2000-05-30
PE4796A1 (es) 1996-03-09
MY113059A (en) 2001-11-30
ZA953627B (en) 1996-11-05
BG100960A (bg) 1997-08-29
SI9520049A (en) 1997-12-31
DK0758244T3 (da) 2002-02-11
CA2189658C (en) 2000-10-31
CZ292360B6 (cs) 2003-09-17
EP0758244B2 (en) 2008-02-13
CN1149831A (zh) 1997-05-14
AP548A (en) 1996-10-30
MA23537A1 (fr) 1995-12-31
TNSN95051A1 (fr) 1996-02-06
FI964452A0 (fi) 1996-11-05
IL131308A0 (en) 2001-01-28
DZ1880A1 (fr) 2002-02-17
HRP950277B1 (en) 2002-06-30
DK0758244T4 (da) 2008-06-16
PL179910B1 (pl) 2000-11-30
UA41995C2 (uk) 2001-10-15
ES2163504T5 (es) 2008-05-16
PT758244E (pt) 2002-04-29
KR970702727A (ko) 1997-06-10
JP2977907B2 (ja) 1999-11-15
NO315453B1 (no) 2003-09-08
LV11729B (en) 1997-08-20
NO964678L (no) 1997-01-06
ATE209497T1 (de) 2001-12-15
EP0758244B1 (en) 2001-11-28
US20020044965A1 (en) 2002-04-18
IL131308A (en) 2001-07-24
AP9500735A0 (en) 1995-04-30
NZ283160A (en) 1998-07-28
NO964678D0 (no) 1996-11-05
CA2189658A1 (en) 1995-11-16
US7108865B2 (en) 2006-09-19
HU9603076D0 (en) 1997-01-28
BG63152B1 (bg) 2001-05-31
OA10320A (en) 1997-10-07
FI964452L (fi) 1996-11-05
IL113516A (en) 2001-04-30
ES2163504T3 (es) 2002-02-01
SK143296A3 (en) 1998-07-08
EP0758244A1 (en) 1997-02-19
CZ324296A3 (cs) 1998-04-15
KR100232297B1 (ko) 1999-12-01
HUT77530A (hu) 1998-05-28
JPH09505609A (ja) 1997-06-03
UY23958A1 (es) 1995-10-31
PL317106A1 (en) 1997-03-17
RU2130311C1 (ru) 1999-05-20
LV11729A (lv) 1997-04-20
DE69524214T2 (de) 2002-05-23
AU2113195A (en) 1995-11-29
CN1096862C (zh) 2002-12-25
CO4290346A1 (es) 1996-04-17
DE69524214D1 (de) 2002-01-10
DE69524214T3 (de) 2008-05-15
BR9501929A (pt) 1996-03-05
TW420616B (en) 2001-02-01
MX9605419A (es) 1997-12-31
SK282854B6 (sk) 2002-12-03
FI964452A7 (fi) 1996-11-05
RO114740B1 (ro) 1999-07-30
IL113516A0 (en) 1995-07-31
AU680356B2 (en) 1997-07-24
HRP950277A2 (en) 1997-10-31

Similar Documents

Publication Publication Date Title
IS4282A (is) Leysnistýrð skammtaform af Azithromycín
NO951952D0 (no) Polykarboksylat
DE69530614D1 (de) Iontophorese pflaster
DK0792253T3 (da) Fremstilling af 11C-methyliodid
DE69502645D1 (de) Fotoempfindliche Zusammensetzung
IT235686Y1 (it) Mattone ventilabile
KR950025196U (ko) 벽돌
KR960022879U (ko) 벽돌
KR960029702U (ko) 클라이스트론
DE59509526D1 (de) Pflasterelement
UA644S (uk) Мікро-еом широкого призначення
KR960003030U (ko) 클라이스트론
KR960006253U (ko) 클라이스트론
KR960003029U (ko) 클라이스트론
KR960011312U (ko) 벽돌
BR7401588U (pt) Tijolo
BR9400356A (pt) Bandagens gessadas
FI951809A0 (fi) Foerfarande och arrangemang i samband med provtagning och provbehandling
FI953696A0 (fi) Foerfarande och anordning i samband med vaetskebehandling
FI954757A0 (fi) Foerfarande i samband med en samlingsvagn och en samlingsvagn
KR970015208U (ko) 클라이스트론
KR960029701U (ko) 클라이스트론
KR970015209U (ko) 클라이스트론
KR960038663U (ko) 클라이스트론
KR970019661U (ko) 클라이스트론